Shanghai Bao Pharmaceuticals Co Ltd
Shanghai Bao Pharmaceuticals Co Ltd is a biotechnology and medical research company that develops and commercializes pharmaceutical products.
Business. Shanghai Bao Pharmaceuticals Co Ltd (2659.HK) is a biotechnology and medical research company headquartered in Shanghai. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments or geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Shanghai Bao Pharmaceuticals Co Ltd (2659.HK) is a biotechnology and medical research company headquartered in Shanghai. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments or geographic revenue mix are not available.
Shanghai Bao Pharmaceuticals Co Ltd has a market capitalization of 8.13 billion CNY, with a market price of 24.94 CNY per share. The company has no dilution risk, as the number of basic and diluted shares outstanding is identical at 325,981,465. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided in the industry configuration. As a result, a direct comparison to cohort medians is not possible. Analysts have assigned a mean recommendation of 2.00, indicating a "Buy" rating, with a mean and median price target of 111.30 CNY, suggesting a significant upside potential.
The company's revenue concentration and geographic exposure are not disclosed in the available data. There is no information on specific segments or geographic regions contributing to revenue, which limits the ability to assess diversification risk.
The company's growth trajectory is not quantified in the outlook section. However, the analyst price targets suggest a strong positive sentiment, with all estimates converging at 111.30 CNY. This implies a consensus view of substantial future value creation.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data. The company is not currently facing high dilution risk, as the number of diluted shares is equal to the number of basic shares. No adjustments have been applied to the valuation metrics, and there is no indication of near-term dilution pressure.
No recent events, such as filings or transcripts, are provided in the input data. Therefore, it is not possible to comment on any recent developments that may have influenced the company's performance or outlook.
- Analysts have assigned a strong "Buy" rating with a mean price target of 111.30 CNY, indicating a significant upside potential.
- The company has no dilution risk, as the number of basic and diluted shares is the same.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
- The company's profitability and return metrics are not available, limiting the ability to compare with industry benchmarks.
- Revenue concentration and geographic exposure are not disclosed, making it difficult to assess diversification risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥49.2M, +698,0% YoY; Operating income −8,3% YoY.
- ▍Revenue ¥49.2M, +698,0% YoY
- ▍Operating income −8,3% YoY
- ▍Net income −8,5% YoY
- ▍Free cash flow −13,5% YoY
- ▍Net margin -804.2%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Shanghai Bao Pharmaceuticals Co Ltd Market data — financials · 2026-05-26
- Shanghai Bao Pharmaceuticals Co Ltd Market data — analyst estimates · 2026-05-26